NCT07136077 2026-04-06
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
7 trialsNCT06848465 2026-04-03
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 1 Recruiting
NCT07468071 2026-04-02
KontRASt-R
Novartis
Phase 1/2 Not yet recruiting
NCT04699188 2026-03-18
KontRASt-01
Novartis
Phase 1/2 Active not recruiting
NCT07453875 2026-03-06
TRIUNITE06
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 1 Not yet recruiting
NCT06356597 2026-02-24
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT05116085 2026-02-13
Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
BeOne Medicines
Phase 2 Completed